OpenNashPodcasts

Topic

AstraZeneca

8 facts from 4 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.

2012

Bancel says he first met AstraZeneca CEO Pascal Soriot at a three-hour breakfast in December 2012 during the partnership talks.

“he set up a breakfast in Gettysburg with Pascal in December of 2012. And so I met Pascal for the first time.”

Stéphane Bancel · Ep11: Stephane Bancel, 0:46:16

2013

Luke Timmerman says Moderna's deal with AstraZeneca included $240 million up front for mRNA drugs across about 40 indications.

“AstraZeneca, $240 million up front to develop mRNAs against something like 40 different indications, cardiovascular, metabolic, and a couple of other things.”

Luke Timmerman · Ep11: Stephane Bancel, 0:35:57

2013

Bancel says Moderna's AstraZeneca deal happened in March 2013, after which the company chose to raise additional money.

“after the AZ deal, which happened in March 13, we decided to raise more money”

Stéphane Bancel · Ep11: Stephane Bancel, 0:54:26

2017

Bancel says Moderna's first successful phase one therapeutic trial was a VEGF program for the heart run with AstraZeneca, meeting its primary and secondary endpoints.

“We had our first phase one for therapeutics that was successful with AstraZeneca for VEGF in the heart, met primary, secondary endpoint.”

Stéphane Bancel · Ep11: Stephane Bancel, 0:05:50

2021

Peter McCullough said the Janssen and AstraZeneca COVID vaccines were made by the same manufacturer, Emergent BioSolutions of Baltimore.

“They were made by the same manufacturer, Emergent Biosolutions out of Baltimore, a biodefense contractor.”

Peter McCullough · #2576 - Dr. Peter McCullough, 1:35:27

2021

Peter McCullough said the adenoviral COVID vaccines were linked to vaccine-induced thrombotic thrombocytopenia (VITT), which he said carried about 30% mortality.

“There's a disease named after it. It's called VITT vaccine-induced thrombotic thrombocytopenia.”

Peter McCullough · #2576 - Dr. Peter McCullough, 1:36:23

2024

AstraZeneca discontinued Byetta, the first approved GLP-1 drug, by 2024.

“by 2024, AZ had quietly discontinued Bayetta, the first CLIP-1 drug ever approved, citing, as you would guess, business reasons.”

Matthew Pech · Episode #1: Amylin Pharmaceuticals, 1:13:09

Episodes